{"trials":[{"id":3621,"nct_id":"NCT06386003","title":"Psilocybin-Assisted Massed Cognitive Processing Therapy for Chronic Posttraumatic Stress Disorder: An Open-label Trial","sponsor":"Unity Health Toronto","registry_url":"https://clinicaltrials.gov/study/NCT06386003","tracker_url":"publication.php?id=3621","status":"ACTIVE_NOT_RECRUITING","status_label":"Active, not recruiting","status_verified_date":"2025-12","last_update_date":"2026-10-06","start_date":"2026-06-01","primary_completion_date":"2028-01","completion_date":"2028-06","study_type":"INTERVENTIONAL","phases":["PHASE2"],"enrollment":{"count":15,"type":"ESTIMATED"},"design":{"allocation":"NA","intervention_model":"SINGLE_GROUP","primary_purpose":"TREATMENT","masking":"NONE"},"conditions":["Post Traumatic Stress Disorder","PTSD","Chronic PTSD"],"interventions":[{"name":"Psilocybin","type":"DRUG"}],"substances":["psilocybin"],"sites":[{"key":"f8718ebbb2d22b3721ee7415ff50f53592161a61926e613b38dcc6395cbf5438","facility":"St. Michael's Hospital, Unity Health Toronto","city":"Toronto","region":"Ontario","country":"Canada","lat":43.706429999999997,"lon":-79.39864}],"countries":["Canada"]},{"id":3490,"nct_id":"NCT07570654","title":"A Phase 2b/3, Multicentre, Randomised, Double-blind, Controlled Trial, With an Open Label Extension, to Investigate the Efficacy, Safety, and Tolerability of COMP360 in Participants With Post-traumatic Stress Disorder","sponsor":"COMPASS Pathways","registry_url":"https://clinicaltrials.gov/study/NCT07570654","tracker_url":"publication.php?id=3490","status":"RECRUITING","status_label":"Recruiting","status_verified_date":"2026-04","last_update_date":"2026-10-06","start_date":"2026-09","primary_completion_date":"2028-11","completion_date":"2029-09","study_type":"INTERVENTIONAL","phases":["PHASE2","PHASE3"],"enrollment":{"count":300,"type":"ESTIMATED"},"design":{"allocation":"RANDOMIZED","intervention_model":"PARALLEL","primary_purpose":"TREATMENT","masking":"QUADRUPLE"},"conditions":["PTSD - Post Traumatic Stress Disorder","PTSD","PTSD Symptoms","PTSD, Post Traumatic Stress Disorder"],"interventions":[{"name":"COMP360 psilocybin","type":"DRUG"}],"substances":["psilocybin"],"sites":[{"key":"ddc0834a1890df449d67ca69d92e76e6f1b5160403493ab29dfc1c2e1aed69c6","facility":"FL","city":"Miami","region":"Florida","country":"United States","lat":25.774270000000001,"lon":-80.193659999999994},{"key":"4b235d9fa455f60193f31a0d89a5dee284e9661ca9046ed4a1e57536aca09d6f","facility":"FL","city":"Orlando","region":"Florida","country":"United States","lat":28.538340000000002,"lon":-81.379239999999996},{"key":"a3f3b33aa62b155795dadc7cd5bdf343b9f66b44bc44a2ad0d5ee5fa338c2557","facility":"IL","city":"Chicago","region":"Illinois","country":"United States","lat":41.850029999999997,"lon":-87.650049999999993},{"key":"dbbb51357e4d710396c355b1f980917dd53615a81be8d319622d67aba5bb4e0e","facility":"MN","city":"Eden Prairie","region":"Minnesota","country":"United States","lat":44.854689999999998,"lon":-93.470789999999994},{"key":"c3798f7e7cf15a4eef1a10f53d46184aaf3eec07c5a23828e9e7a968feadf7db","facility":"NE","city":"Lincoln","region":"Nebraska","country":"United States","lat":40.799999999999997,"lon":-96.666960000000003},{"key":"1d793527c906ffb5c84860c6577d23027344e23eb25b29e2b74f8a07d64f5514","facility":"NV","city":"Las Vegas","region":"Nevada","country":"United States","lat":36.174970000000002,"lon":-115.13722},{"key":"6214ddb8e0d6a9b9b5b4cd7c9be7f1b1f04d1f4f17ff5715a68f589a0d3c671a","facility":"NY","city":"New York","region":"New York","country":"United States","lat":40.714269999999999,"lon":-74.005970000000005},{"key":"593189837e8532b432a369deaaa9a95dd6d9069e9ee0f7d4f302734d14cb430e","facility":"BC","city":"North Vancouver","region":"British Columbia","country":"Canada","lat":49.316360000000003,"lon":-123.06934}],"countries":["United States","Canada"]},{"id":3660,"nct_id":"NCT07332143","title":"The Safety and Acceptability of Psilocybin With Support and With Massed Prolonged Exposure Therapy for PTSD","sponsor":"Emory University","registry_url":"https://clinicaltrials.gov/study/NCT07332143","tracker_url":"publication.php?id=3660","status":"RECRUITING","status_label":"Recruiting","status_verified_date":"2026-09","last_update_date":"2026-10-01","start_date":"2026-06-08","primary_completion_date":"2027-03","completion_date":"2027-03","study_type":"INTERVENTIONAL","phases":["PHASE2"],"enrollment":{"count":150,"type":"ESTIMATED"},"design":{"allocation":"RANDOMIZED","intervention_model":"PARALLEL","primary_purpose":"TREATMENT","masking":"NONE"},"conditions":["PTSD"],"interventions":[{"name":"psilocybin","type":"DRUG"},{"name":"Supportive Therapy","type":"BEHAVIORAL"},{"name":"Prolonged Exposure Therapy","type":"BEHAVIORAL"}],"substances":["psilocybin"],"sites":[{"key":"8d12e2a0185c4db904e4654a720cc76843665c984d8a6666af2af6398451abcf","facility":"Emory University Hospital","city":"Atlanta","region":"Georgia","country":"United States","lat":33.749000000000002,"lon":-84.387979999999999}],"countries":["United States"]},{"id":3485,"nct_id":"NCT06853912","title":"PsiloStudy: A Phase 2 Single-site, Double-blind, Placebo-controlled, Randomized Clinical Trial With an Open-label Extension Phase to Examine the Safety, Subjective Experiences, Acute Effects, and Suitability of Psilocybin Combined With Psychological Support (Psi-PS) for Military Veterans and First Responders With Co-occurring Alcohol Use Disorder (AUD) and Posttraumatic Stress Disorder (PTSD)","sponsor":"Nathan Brashares Sackett","registry_url":"https://clinicaltrials.gov/study/NCT06853912","tracker_url":"publication.php?id=3485","status":"ACTIVE_NOT_RECRUITING","status_label":"Active, not recruiting","status_verified_date":"2026-08","last_update_date":"2026-08-13","start_date":"2025-06-01","primary_completion_date":"2026-11-01","completion_date":"2027-06-01","study_type":"INTERVENTIONAL","phases":["PHASE2"],"enrollment":{"count":40,"type":"ESTIMATED"},"design":{"allocation":"RANDOMIZED","intervention_model":"PARALLEL","primary_purpose":"TREATMENT","masking":"DOUBLE"},"conditions":["Alcohol Use Disorder (AUD)","PTSD"],"interventions":[{"name":"Psilocybin 25 mg","type":"DRUG"},{"name":"Maltodextrin (Placebo)","type":"DRUG"}],"substances":["psilocybin"],"sites":[{"key":"7de3d89eed44865c013d4553fc6090d54c7c067dbeedefce79bfea681d8b54c2","facility":"University of Washington Center for Novel Therapeutics in Addiction Psychiatry","city":"Seattle","region":"Washington","country":"United States","lat":47.606209999999997,"lon":-122.33207}],"countries":["United States"]},{"id":5846,"nct_id":"NCT07745569","title":"Precision Phenotyping of Behavioral Risk and Response to Electromagnetic and Psychedelic Therapies","sponsor":"University of New Mexico","registry_url":"https://clinicaltrials.gov/study/NCT07745569","tracker_url":"publication.php?id=5846","status":"NOT_YET_RECRUITING","status_label":"Not yet recruiting","status_verified_date":"2026-07","last_update_date":"2026-08-04","start_date":"2026-08-31","primary_completion_date":"2030-06-30","completion_date":"2030-06-30","study_type":"INTERVENTIONAL","phases":["PHASE2"],"enrollment":{"count":150,"type":"ESTIMATED"},"design":{"allocation":"NON_RANDOMIZED","intervention_model":"PARALLEL","primary_purpose":"TREATMENT","masking":"NONE"},"conditions":["PTSD","PTSD - Post Traumatic Stress Disorder","Major Depression","Suicidality"],"interventions":[{"name":"Transcranial Magnetic Stimulation","type":"DEVICE"},{"name":"Psilocybin (drug)","type":"DRUG"},{"name":"Neurofeedback","type":"BEHAVIORAL"}],"substances":["psilocybin"],"sites":[],"countries":[]},{"id":3654,"nct_id":"NCT07275970","title":"An Open-Label, Phase 1 Study of the Safety Pharmacokinetic Profile, and Preliminary Efficacy, of Organic Whole Psilocybin-Containing Mushrooms in Patients Suffering From PTSD","sponsor":"Scottsdale Research Institute","registry_url":"https://clinicaltrials.gov/study/NCT07275970","tracker_url":"publication.php?id=3654","status":"ACTIVE_NOT_RECRUITING","status_label":"Active, not recruiting","status_verified_date":"2026-07","last_update_date":"2026-07-29","start_date":"2026-03-20","primary_completion_date":"2026-07-30","completion_date":"2026-10-01","study_type":"INTERVENTIONAL","phases":["PHASE1"],"enrollment":{"count":24,"type":"ESTIMATED"},"design":{"allocation":"NA","intervention_model":"SINGLE_GROUP","primary_purpose":"TREATMENT","masking":"NONE"},"conditions":["PTSD"],"interventions":[{"name":"Psychedelic","type":"DRUG"}],"substances":["psilocybin"],"sites":[{"key":"a702953addaa4dc3d8c52c701265782e11a96d5e3dba6aa4403c50eb6c2871a1","facility":"Scottsdale Research Institute","city":"Scottsdale","region":"Arizona","country":"United States","lat":33.509210000000003,"lon":-111.89903}],"countries":["United States"]},{"id":3537,"nct_id":"NCT06624137","title":"Computationally, Electrophysiologically, and Qualitatively Characterizing Serotonergic Psychedelics; Transdiagnostic Therapeutic and Pro-Psychotic Effects","sponsor":"Yale University","registry_url":"https://clinicaltrials.gov/study/NCT06624137","tracker_url":"publication.php?id=3537","status":"TERMINATED","status_label":"Terminated","status_verified_date":"2026-07","last_update_date":"2026-07-09","start_date":"2024-12-12","primary_completion_date":"2026-06-14","completion_date":"2026-06-14","study_type":"OBSERVATIONAL","phases":[],"enrollment":{"count":5,"type":"ACTUAL"},"design":{"allocation":"","intervention_model":"","primary_purpose":"","masking":""},"conditions":["OCD","Major Depressive Disorder (MDD)","Alcohol Use Disorder (AUD)","Healthy Volunteer","Migraine","PTSD","PTSD - Post Traumatic Stress Disorder","Addiction","Tobacco Use Disorder","Obsessive Compulsive Disorder (OCD)","Opioid Use Disorder"],"interventions":[{"name":"Serotonergic Psychedelic","type":"DRUG"},{"name":"Placebo","type":"DRUG"}],"substances":["psilocybin"],"sites":[{"key":"20e312916f86cde9502fe213560fb5cb84834cd4665474a7d3a3ea662605a54d","facility":"Connecticut Mental Health Center","city":"Hamden","region":"Connecticut","country":"United States","lat":41.39593,"lon":-72.896770000000004},{"key":"a17b95243bab2667321a9c9da83c8ea1ac3e43c5e4a76ea01bb2eaf6e4cac641","facility":"West Haven VA Medical Center","city":"West Haven","region":"Connecticut","country":"United States","lat":41.270650000000003,"lon":-72.947050000000004}],"countries":["United States"]},{"id":3547,"nct_id":"NCT06902974","title":"A Phase 2, Open-Label Study Investigating the Safety and Efficacy of Psilocybin-Assisted Therapy for Sexual Assault-Related Posttraumatic Stress Disorder (PTSD)","sponsor":"Sunstone Medical","registry_url":"https://clinicaltrials.gov/study/NCT06902974","tracker_url":"publication.php?id=3547","status":"RECRUITING","status_label":"Recruiting","status_verified_date":"2026-06","last_update_date":"2026-07-01","start_date":"2026-05-23","primary_completion_date":"2027-11","completion_date":"2028-05","study_type":"INTERVENTIONAL","phases":["PHASE2"],"enrollment":{"count":70,"type":"ESTIMATED"},"design":{"allocation":"NA","intervention_model":"SINGLE_GROUP","primary_purpose":"TREATMENT","masking":"NONE"},"conditions":["Post Traumatic Stress Disorder","PTSD"],"interventions":[{"name":"Psilocybin 25 mg","type":"DRUG"}],"substances":["psilocybin"],"sites":[{"key":"8bf6e838a381bd54a71fab76ec32329ee9e85502264bce18bfd4dce5416f5ef3","facility":"Sunstone Medical, PC","city":"Rockville","region":"Maryland","country":"United States","lat":39.084000000000003,"lon":-77.152760000000001}],"countries":["United States"]},{"id":3614,"nct_id":"NCT07506395","title":"Group Psilocybin-Assisted Therapy for Post-Traumatic Stress Disorder","sponsor":"University of New Mexico","registry_url":"https://clinicaltrials.gov/study/NCT07506395","tracker_url":"publication.php?id=3614","status":"RECRUITING","status_label":"Recruiting","status_verified_date":"2026-05","last_update_date":"2026-05-22","start_date":"2026-05-01","primary_completion_date":"2027-05-01","completion_date":"2028-05-01","study_type":"INTERVENTIONAL","phases":["PHASE1"],"enrollment":{"count":36,"type":"ESTIMATED"},"design":{"allocation":"NA","intervention_model":"SINGLE_GROUP","primary_purpose":"TREATMENT","masking":"NONE"},"conditions":["PTSD"],"interventions":[{"name":"Psilocybin","type":"DRUG"}],"substances":["psilocybin"],"sites":[{"key":"1a9055771782109a22253dda7644c3735bc7758f34ad52e7af1cb4208b995f4b","facility":"Interdisciplinary Substance Use and Brain Injury (ISUBI)","city":"Albuquerque","region":"New Mexico","country":"United States","lat":35.084490000000002,"lon":-106.65114}],"countries":["United States"]},{"id":3473,"nct_id":"NCT06442423","title":"Safety, Feasibility, and Tolerability of Psilocybin Treatment for Individuals With Functional Impairment Related to Mood, Anxiety, Trauma and/or Addiction Symptoms: An Open-label Proof-of-concept Study","sponsor":"Yale University","registry_url":"https://clinicaltrials.gov/study/NCT06442423","tracker_url":"publication.php?id=3473","status":"RECRUITING","status_label":"Recruiting","status_verified_date":"2026-03","last_update_date":"2026-03-11","start_date":"2024-10-17","primary_completion_date":"2027-12","completion_date":"2027-12","study_type":"INTERVENTIONAL","phases":["PHASE1"],"enrollment":{"count":50,"type":"ESTIMATED"},"design":{"allocation":"NA","intervention_model":"SINGLE_GROUP","primary_purpose":"TREATMENT","masking":"NONE"},"conditions":["Transdiagnostic","Depression - Major Depressive Disorder","Anxiety","PTSD Symptoms","PTSD","Substance Use","Substance Use Disorder (SUD)","OCD"],"interventions":[{"name":"Psilocybin","type":"DRUG"}],"substances":["psilocybin"],"sites":[{"key":"53cb5faca3c60ecf068797736403edeb0302d95d0a85337b9536bbc345ef7916","facility":"Connecticut Mental Health Center - Yale School of Medicine","city":"New Haven","region":"Connecticut","country":"United States","lat":41.308149999999998,"lon":-72.928160000000005}],"countries":["United States"]},{"id":3497,"nct_id":"NCT05554094","title":"Examining the Safety and Clinical Efficacy of Psilocybin Therapy for Veterans With PTSD: An Open-Label Proof-of-Concept Trial","sponsor":"Ohio State University","registry_url":"https://clinicaltrials.gov/study/NCT05554094","tracker_url":"publication.php?id=3497","status":"ACTIVE_NOT_RECRUITING","status_label":"Active, not recruiting","status_verified_date":"2025-10","last_update_date":"2026-03-04","start_date":"2023-01-01","primary_completion_date":"2025-12-31","completion_date":"2026-07-31","study_type":"INTERVENTIONAL","phases":["PHASE2"],"enrollment":{"count":15,"type":"ESTIMATED"},"design":{"allocation":"NA","intervention_model":"SINGLE_GROUP","primary_purpose":"TREATMENT","masking":"NONE"},"conditions":["PTSD","Stress Disorders, Traumatic","Stress Disorders, Post-Traumatic","Trauma and Stressor Related Disorders","Mental Disorder"],"interventions":[{"name":"Psilocybin","type":"DRUG"}],"substances":["psilocybin"],"sites":[{"key":"281c2eb56c8da95ba692a4789013f5bedb7069494aeb666eb410ca73d4c419da","facility":"Ohio State University Department of Psychiatry and Behavioral Health at the Davis Medical Research Center","city":"Columbus","region":"Ohio","country":"United States","lat":39.961179999999999,"lon":-82.99879}],"countries":["United States"]},{"id":3703,"nct_id":"NCT06888128","title":"The STARLIGHT Protocol: State-Funded Trial Assessing Recovery and Long-Term Impact of Guided Psilocybin for Healing Trauma","sponsor":"Baylor College of Medicine","registry_url":"https://clinicaltrials.gov/study/NCT06888128","tracker_url":"publication.php?id=3703","status":"RECRUITING","status_label":"Recruiting","status_verified_date":"2026-01","last_update_date":"2026-01-22","start_date":"2025-01-30","primary_completion_date":"2026-12-15","completion_date":"2026-12-15","study_type":"INTERVENTIONAL","phases":["PHASE2"],"enrollment":{"count":15,"type":"ESTIMATED"},"design":{"allocation":"NA","intervention_model":"SINGLE_GROUP","primary_purpose":"TREATMENT","masking":"NONE"},"conditions":["PTSD"],"interventions":[{"name":"Psilocybin 15mg","type":"DRUG"},{"name":"Psilocybin 25mg","type":"DRUG"}],"substances":["psilocybin"],"sites":[{"key":"e9371a41662463aee2a73b489b08fd54498561d5f98b540ab6947525b5b46514","facility":"Baylor College of Medicine","city":"Houston","region":"Texas","country":"United States","lat":29.763280000000002,"lon":-95.36327}],"countries":["United States"]},{"id":3475,"nct_id":"NCT05876481","title":"Evaluation of the Acceptability, Safety, Feasibility, and Efficacy of Psilocybin-assisted Psychotherapy (PaP) for the Treatment of Post-traumatic Stress Disorder (PTSD) in Military Veterans","sponsor":"Combat Stress","registry_url":"https://clinicaltrials.gov/study/NCT05876481","tracker_url":"publication.php?id=3475","status":"UNKNOWN","status_label":"Unknown status","status_verified_date":"2023-05","last_update_date":"2023-05-25","start_date":"2023-06","primary_completion_date":"2025-07","completion_date":"2025-08","study_type":"INTERVENTIONAL","phases":["PHASE2"],"enrollment":{"count":8,"type":"ESTIMATED"},"design":{"allocation":"NA","intervention_model":"SINGLE_GROUP","primary_purpose":"TREATMENT","masking":"NONE"},"conditions":["PTSD"],"interventions":[{"name":"Psilocybin","type":"DRUG"}],"substances":["psilocybin"],"sites":[{"key":"9b630a2a90cc4073ef88d0ddbb37bf0acd68f69db35ab18518826ea459738714","facility":"Combat Stress","city":"Leatherhead","region":"Surrey","country":"United Kingdom","lat":51.296520000000001,"lon":-0.33379999999999999}],"countries":["United Kingdom"]}],"facets":{"countries":{"United States":182,"Canada":41,"Switzerland":21,"United Kingdom":18,"France":7,"Denmark":7,"Netherlands":6,"Czechia":5,"Ireland":5,"Sweden":4,"Israel":4,"Germany":3,"Australia":3,"Spain":2,"Brazil":2,"Pakistan":2,"Portugal":2,"Belgium":2,"Poland":1,"Austria":1,"New Zealand":1,"Finland":1,"Jordan":1,"Jamaica":1,"Argentina":1},"sponsors":{"Johns Hopkins University":31,"Yale University":16,"University Hospital, Basel, Switzerland":13,"COMPASS Pathways":9,"University of Wisconsin, Madison":9,"NYU Langone Health":9,"Centre for Addiction and Mental Health":8,"University Health Network, Toronto":5,"University of Calgary":5,"King's College London":5,"University of Washington":5,"Imperial College London":5,"University of Zurich":5,"MycoMedica Life Sciences PBC":4,"Joshua Woolley, MD, PhD":4,"University of New Mexico":4,"Usona Institute":4,"Centre Hospitalier Universitaire de Nīmes":4,"Washington University School of Medicine":4,"University of California, Los Angeles":4,"M.D. Anderson Cancer Center":3,"University of Colorado, Denver":3,"University of California, San Diego":3,"University of Alabama at Birmingham":3,"Sheppard Pratt Health System":3,"Unity Health Toronto":2,"University of British Columbia":2,"Emory University":2,"University of Minnesota":2,"Charles Raison":2,"Yvan Beaussant, MD, MSci":2,"Francisco A Moreno":2,"Ohio State University":2,"Khyber Medical University Peshawar":2,"University of California, Berkeley":2,"Sunstone Medical":2,"Robin Carhart-Harris, PhD, MA":2,"Section for Affective Disorders; Northern Stockholm Psychiatry":2,"Anders Fink-Jensen, MD, DMSci":2,"TRYP Therapeutics":2,"Beersheva Mental Health Center":2,"University of California, San Francisco":2,"Gitte Moos Knudsen":2,"University of Utah":2,"Brown University":1,"National Institute on Aging (NIA)":1,"Brigham and Women's Hospital":1,"Oregon Health and Science University":1,"Peter Hendricks":1,"Centre Hospitalier St Anne":1,"Lakshmi N Yatham":1,"Jennifer Mitchell":1,"McMaster University":1,"ARQ National Psychotrauma Centre":1,"University of Nebraska":1,"Region Skane":1,"VA Office of Research and Development":1,"Rachel Yehuda":1,"Sharmin Ghaznavi":1,"Nathan Brashares Sackett":1,"The University of Texas Health Science Center, Houston":1,"Roswell Park Cancer Institute":1,"Claudio N Soares":1,"Nicky Mehtani, MD, MPH":1,"James J. Peters Veterans Affairs Medical Center":1,"Trent Emerick":1,"University of Southern California":1,"Joshua Rosenblat":1,"Tel-Aviv Sourasky Medical Center":1,"Scottsdale Research Institute":1,"Pontifícia Universidade Católica do Rio de Janeiro":1,"Diamond Therapeutics Inc.":1,"Bruyère Health Research Institute.":1,"Ottawa Hospital Research Institute":1,"University of Pennsylvania":1,"Anthony P King":1,"University of Virginia":1,"Manoj Doss":1,"Alan Davis":1,"University Medical Center Groningen":1,"University of North Carolina, Chapel Hill":1,"Stanford University":1,"Portland VA Research Foundation, Inc":1,"Kyle Greenway":1,"Sunnybrook Health Sciences Centre":1,"Indiana University":1,"Federal University of Latin American Integration":1,"Medical University of Vienna":1,"Gustavo Vazquez":1,"Psyence Australia Pty Ltd":1,"Marissa Raymond-Flesch, MD, MPH":1,"Gabriella Gobbi":1,"Hadassah Medical Organization":1,"Nantes University Hospital":1,"Baylor College of Medicine":1,"Rotem Petranker":1,"University of Chicago":1,"University of Iowa":1,"University College, London":1,"University of Texas at Austin":1,"Charles S. Grob, M.D.":1,"Peggy C Nopoulos":1,"Anna Rose Childress, Ph.D.":1,"Kevin Murnane":1,"University Hospital, Geneva":1,"Healing Advocacy Fund":1,"Maastricht University":1,"Matthew Hicks":1,"National University of Natural Medicine":1,"Icahn School of Medicine at Mount Sinai":1,"Kevin Boehnke":1,"Felix Mueller":1,"University of Otago":1,"Insel Gruppe AG, University Hospital Bern":1,"Lundquist Institute for Biomedical Innovation at Harbor-UCLA Medical Center":1,"Central Institute of Mental Health, Mannheim":1,"Filament Health Corp.":1,"Western University, Canada":1,"University Hospital, Ghent":1,"University of Arizona":1,"Clairvoyant Therapeutics":1,"Brugmann University Hospital":1,"Empower Research Inc":1,"University of Sydney":1,"Nova Mentis Life Science Corp":1,"Massachusetts General Hospital":1,"Multidisciplinary Association for Psychedelic Studies":1,"Apex Labs Ltd.":1,"Milan Scheidegger":1,"Lobe Sciences Ltd.":1,"Brain and Cognition Discovery Foundation":1,"The Roots to Thrive Society for Psychedelic Therapy":1,"Cybin Therapeutics Inc.":1,"Halucenex Life Sciences Inc.":1,"Combat Stress":1,"Optimi Health Corporation":1,"New York State Psychiatric Institute":1,"Keith Heinzerling":1,"NWTraumatherapies":1,"Beckley Psytech Limited":1,"Wake Network, Inc.":1,"National Institute of Mental Health, Czech Republic":1,"National Council of Scientific and Technical Research, Argentina":1,"Maryland Oncology Hematology, PA":1,"Joshua Woolley":1,"University of Helsinki":1},"phases":{"PHASE2":157,"PHASE1":112,"EARLY_PHASE1":24,"NA":16,"PHASE3":12},"conditions":{"Healthy":26,"Depression":23,"Major Depressive Disorder":23,"Treatment Resistant Depression":20,"PTSD":13,"Alcohol Use Disorder":13,"Anxiety":13,"Psilocybin":12,"Psychedelic Experiences":9,"Opioid Use Disorder":9,"Post Traumatic Stress Disorder":7,"Depression - Major Depressive Disorder":7,"Obsessive-Compulsive Disorder":6,"Advanced Cancer":6,"Demoralization":6,"Anorexia Nervosa":6,"Cancer":6,"Healthy Volunteers":5,"Depressive Disorder":5,"PTSD - Post Traumatic Stress Disorder":4,"Methamphetamine Use Disorder":4,"Anhedonia":4,"Psychological Distress":4,"Alcohol Use Disorder (AUD)":4,"Hematopoietic and Lymphatic System Neoplasm":4,"Depressive Disorder, Major":4,"Major Depressive Disorder (MDD)":4,"Alcohol Dependence":4,"Depressive Symptoms":3,"Suicidal Ideation":3,"Healthy Volunteer":3,"Stage IV Melanoma":3,"Major Depression":3,"Pain Management":3,"Metastatic Malignant Solid Neoplasm":3,"Chronic Pain":3,"Fibromyalgia":3,"PTSD Symptoms":2,"Nicotine Dependence":2,"Borderline Personality Disorder":2,"Treatment-resistant Depression (TRD)":2,"Stage IV Solid Tumor Cancer":2,"Stage IV Sarcoma of Bone":2,"Stage IV Lymphoma":2,"Endocrine Cancer":2,"Psychedelic Effects in Healthy Volunteers":2,"Depression, Anxiety":2,"Chronic Low-back Pain":2,"Parkinson Disease":2,"Existential Distress":2,"Treatment-Resistant Depression":2,"Aging":2,"Bipolar II Disorder":2,"Suicidality":2,"Malignant Solid Neoplasm":2,"Autism Spectrum Disorder":2,"Migraine":2,"Grief":2,"OCD":2,"Addiction":2,"Tobacco Use Disorder":2,"Substance Use Disorders":2,"Treatment-resistant Depression":2,"Treatment-Resistant Major Depressive Disorder":2,"MDD":2,"Substance Use Disorder (SUD)":2,"Healthy Participants":2,"Anxiety Disorders":2,"Depressive Disorder, Treatment-Resistant":2,"Hallucinogens":2,"Sleep":2,"Burnout, Professional":2,"Migraine Headache":2,"Cluster Headache":2,"Mood Change":2,"Phase I":1,"Alzheimer's Disease":1,"Chronic PTSD":1,"PTSD, Post Traumatic Stress Disorder":1,"Amnestic Mild Cognitive Impairment":1,"Neuropathy":1,"Mood (Psychological Function)":1,"Well Being":1,"Mood":1,"Well-Being, Psychological":1,"Parkinson's Disease (PD)":1,"Psychedelic Microdosing Effects on Mood, Cognition, Subjective Well-being and MRI":1,"Chronic Pelvic Pain":1,"Borderline Personality Pathology":1,"Emotion Dysregulation":1,"Older Adults (65-85 Years)":1,"Music Intervention":1,"Emotional Blunting":1,"Bipolar II Depression":1,"Premenstrual Dysphoric Disorder ( PMDD)":1,"PMDD":1,"Psilocybin-Assisted Psychotherapy":1,"Persisting Symptoms After Concussion":1,"Anhedonia in Healthy Volunteers":1,"Older Adults (50-90 Years)":1,"Post Traumatic Stress Disorder PTSD":1,"Intimate Partner Violence (IPV)":1,"Alzheimer Disease":1,"Mild Cognitive Impairment":1,"Posttraumatic Stress Disorder":1,"Breast Cancer":1,"Ovarian Cancer":1,"Investigating the Importance of the Subjective Psychedelic Experience":1,"Burnout":1,"Burnout, Healthcare Workers":1,"Cannabis Use Disorder, Moderate":1,"Cannabis Use Disorder, Severe":1,"Posttraumatic Stress Disorder (PTSD)":1,"Chronic Low Back Pain (CLBP)":1,"Physical Therapy":1,"Pancreas Cancer":1,"Biliary Tract Cancer":1,"Gastrointestinal Cancer":1,"Longevity":1,"Biomarkers of Aging":1,"Psychological Stress":1,"Depression, Bipolar":1,"Generalized Anxiety Disorder (GAD)":1,"Human Immunodeficiency Virus (HIV)":1,"Amyotrophic Lateral Sclerosis":1,"Spinal Cord Injury":1,"Veteran":1,"Bipolar Depression":1,"Postoperative Pain":1,"Mental Health":1,"Opioid-Related Disorders":1,"Pain Management and Care":1,"Advanced Cancers":1,"Smokers With Chronic Pain":1,"Post-Traumatic Stress Disorder, PTSD":1,"Vagus Nerve Stimulation":1,"Healthy Adults":1,"Functional Neurological Disorder":1,"Healthy Controls":1,"Post-Traumatic Stress Disorder (PTSD)":1,"Distress, Emotional":1,"Perception Disorders":1,"Loneliness":1,"Mood Disorders":1,"Obsessive Compulsive Disorder (OCD)":1,"Depressive Sympotoms":1,"Caregiver Distress":1,"Prolonged Grief Disorder":1,"Neuroimaging":1,"Healthy Participants With Lower-than-average Mental Well-being":1,"Cocaine-Related Disorders":1,"Lung Non-Small Cell Carcinoma":1,"Unipolar Depression":1,"Obsessive - Compulsive Disorder":1,"Substance-Related Disorders":1,"Chemically-Induced Disorders":1,"Stimulant-Use Disorder":1,"COPD (Chronic Obstructive Pulmonary Disease)":1,"ALS (Amyotrophic Lateral Sclerosis)":1,"MS (Multiple Sclerosis)":1,"Atypical Parkinson Disease":1,"Refractory Depression":1,"Cognitive Behavioral Therapy":1,"Palliative Care":1,"Pain":1,"Quality of Life":1,"Caregiver Burden":1,"Fear of Death":1,"Amphetamine-Related Disorders":1,"Cocaine Use Disorder":1,"Cannabis Use Disorder":1,"Safety":1,"Fibromyalgia, Primary":1,"Transdiagnostic":1,"Substance Use":1,"IBS - Irritable Bowel Syndrome":1,"Stress Disorders, Traumatic":1,"Stress Disorders, Post-Traumatic":1,"Trauma and Stressor Related Disorders":1,"Mental Disorder":1,"Adjustment Disorder":1,"Adjustment Disorder With Anxious Mood":1,"Cancer Cachexia":1,"Cancer of Endometrium":1,"Cancer of Kidney":1,"Cancer of Prostate":1,"Cancer of the Breast":1,"Cancer of Stomach":1,"Cancer Melanoma Skin":1,"Cancer Pancreas":1,"Placebo - Control":1,"Hospice":1,"Terminal Illness":1,"Cancer-related Problem/Condition":1,"Psychotherapy":1,"Terminal Cancer":1,"Cancer Terminal":1,"Stroke":1,"Chronic Stroke":1,"Intracerebral Haemorrhage":1,"Intracerebral Haemorrhage (ICH)":1,"Intracerebral Hemorrhage Basal Ganglia":1,"Ischemic Stroke":1,"Ischemic Stroke and Hemorrhagic Stroke":1,"Hemiparesis After Stroke":1,"Hemiplegia Following Ischemic Stroke":1,"Hemiplegia and Hemiparesis":1,"Hemiplegia and/or Hemiparesis Following Stroke":1,"Middle Cerebral Artery Stroke":1,"Major Depressive Diorder":1,"Irritable Bowel Syndrome":1,"Gambling Disorder":1,"Phantom Limb Pain":1,"Stuttering":1,"Self Harm":1,"Opioid Dependence":1,"Alcohol Abuse":1,"Recurrent Depression":1,"Obsessive-compulsive Disorder":1,"Psychogenic Nonepileptic Seizures":1,"Reinforcement, Psychology":1,"Post-Treatment Lyme Disease":1,"Chronic Lyme Disease":1,"Lyme Disease, Chronic":1,"Hematopoietic and Lymphoid Cell Neoplasm":1,"Perception Disturbance":1,"Visual Suppression":1,"Meditation":1,"Microdosing":1,"Personal Experience of Substance-assisted Therapy Using Psilocybin, MDMA, and LSD":1,"Chronic Neuropathic Pain":1,"Neuropharmacological Investigation of Ayahuasca Constituents DMT and Harmine":1,"Alcohol-Related Disorders":1,"Burnout, Caregiver":1,"COVID-19":1,"Moral Injury":1,"Basic Science":1,"Binge Eating Disorder":1,"Stimulant Use Disorder":1,"Disorders of Consciousness":1,"Obsessive-compulsive Disorder (OCD)":1,"Severe Alcohol Use Disorder":1,"Psychotherapy, Group":1,"Fragile X Syndrome":1,"Behavior":1,"Cognitive Dysfunction":1,"Alcoholism":1,"Post-Traumatic Stress Disorder":1,"Post-traumatic Stress Disorder":1,"Post-Traumatic Headache":1,"Side Effect of Drug":1,"QTc Interval":1,"Pharmacokinetics":1,"End of Life":1,"Mild Depression":1,"Moderate Depression":1,"Treatment Resistant Disorders":1,"Amnesia":1,"Mood Disturbance":1,"Sleep Disturbance":1,"Drug Effect":1,"Health, Subjective":1,"Psilocin Toxicity":1,"Psilocybin Toxicity":1,"Psilocybin Causing Adverse Effects in Therapeutic Use":1,"Body Dysmorphic Disorders":1,"Trauma, Nervous System":1,"Short Lasting Unilateral Neuralgiform Headache Attacks":1,"Anxiety and Depression":1,"Religious or Spiritual Problem":1,"Patients":1,"Cognitive Change":1,"Creativity":1,"Altered Waking States of Consciousness in Healthy Humans":1,"Distress":1,"Parkinson Disease Psychosis":1,"Severe Depression":1,"Pharmacologic Actions":1,"Central Nervous System Agents":1,"Therapeutic Uses":1,"Psychotropic Drugs":1},"statuses":{"RECRUITING":103,"COMPLETED":97,"ACTIVE_NOT_RECRUITING":33,"NOT_YET_RECRUITING":33,"UNKNOWN":16,"WITHDRAWN":14,"TERMINATED":7,"ENROLLING_BY_INVITATION":3,"SUSPENDED":2}},"years":{"2023":2,"2024":2,"2025":2,"2026":7},"statuses":{"Recruiting":6,"Active, not recruiting":4,"Not yet recruiting":1,"Terminated":1,"Unknown status":1},"conditions":{"PTSD":13,"PTSD - Post Traumatic Stress Disorder":3,"Post Traumatic Stress Disorder":2,"PTSD Symptoms":2,"Alcohol Use Disorder (AUD)":2,"OCD":2,"Chronic PTSD":1,"PTSD, Post Traumatic Stress Disorder":1,"Major Depression":1,"Suicidality":1,"Major Depressive Disorder (MDD)":1,"Healthy Volunteer":1,"Migraine":1,"Addiction":1,"Tobacco Use Disorder":1,"Obsessive Compulsive Disorder (OCD)":1,"Opioid Use Disorder":1,"Transdiagnostic":1,"Depression - Major Depressive Disorder":1,"Anxiety":1,"Substance Use":1,"Substance Use Disorder (SUD)":1,"Stress Disorders, Traumatic":1,"Stress Disorders, Post-Traumatic":1,"Trauma and Stressor Related Disorders":1,"Mental Disorder":1},"sites":[{"key":"f8718ebbb2d22b3721ee7415ff50f53592161a61926e613b38dcc6395cbf5438","facility":"St. Michael's Hospital, Unity Health Toronto","city":"Toronto","region":"Ontario","country":"Canada","lat":43.706429999999997,"lon":-79.39864},{"key":"ddc0834a1890df449d67ca69d92e76e6f1b5160403493ab29dfc1c2e1aed69c6","facility":"FL","city":"Miami","region":"Florida","country":"United States","lat":25.774270000000001,"lon":-80.193659999999994},{"key":"4b235d9fa455f60193f31a0d89a5dee284e9661ca9046ed4a1e57536aca09d6f","facility":"FL","city":"Orlando","region":"Florida","country":"United States","lat":28.538340000000002,"lon":-81.379239999999996},{"key":"a3f3b33aa62b155795dadc7cd5bdf343b9f66b44bc44a2ad0d5ee5fa338c2557","facility":"IL","city":"Chicago","region":"Illinois","country":"United States","lat":41.850029999999997,"lon":-87.650049999999993},{"key":"dbbb51357e4d710396c355b1f980917dd53615a81be8d319622d67aba5bb4e0e","facility":"MN","city":"Eden Prairie","region":"Minnesota","country":"United States","lat":44.854689999999998,"lon":-93.470789999999994},{"key":"c3798f7e7cf15a4eef1a10f53d46184aaf3eec07c5a23828e9e7a968feadf7db","facility":"NE","city":"Lincoln","region":"Nebraska","country":"United States","lat":40.799999999999997,"lon":-96.666960000000003},{"key":"1d793527c906ffb5c84860c6577d23027344e23eb25b29e2b74f8a07d64f5514","facility":"NV","city":"Las Vegas","region":"Nevada","country":"United States","lat":36.174970000000002,"lon":-115.13722},{"key":"6214ddb8e0d6a9b9b5b4cd7c9be7f1b1f04d1f4f17ff5715a68f589a0d3c671a","facility":"NY","city":"New York","region":"New York","country":"United States","lat":40.714269999999999,"lon":-74.005970000000005},{"key":"593189837e8532b432a369deaaa9a95dd6d9069e9ee0f7d4f302734d14cb430e","facility":"BC","city":"North Vancouver","region":"British Columbia","country":"Canada","lat":49.316360000000003,"lon":-123.06934},{"key":"8d12e2a0185c4db904e4654a720cc76843665c984d8a6666af2af6398451abcf","facility":"Emory University Hospital","city":"Atlanta","region":"Georgia","country":"United States","lat":33.749000000000002,"lon":-84.387979999999999},{"key":"7de3d89eed44865c013d4553fc6090d54c7c067dbeedefce79bfea681d8b54c2","facility":"University of Washington Center for Novel Therapeutics in Addiction Psychiatry","city":"Seattle","region":"Washington","country":"United States","lat":47.606209999999997,"lon":-122.33207},{"key":"a702953addaa4dc3d8c52c701265782e11a96d5e3dba6aa4403c50eb6c2871a1","facility":"Scottsdale Research Institute","city":"Scottsdale","region":"Arizona","country":"United States","lat":33.509210000000003,"lon":-111.89903},{"key":"20e312916f86cde9502fe213560fb5cb84834cd4665474a7d3a3ea662605a54d","facility":"Connecticut Mental Health Center","city":"Hamden","region":"Connecticut","country":"United States","lat":41.39593,"lon":-72.896770000000004},{"key":"a17b95243bab2667321a9c9da83c8ea1ac3e43c5e4a76ea01bb2eaf6e4cac641","facility":"West Haven VA Medical Center","city":"West Haven","region":"Connecticut","country":"United States","lat":41.270650000000003,"lon":-72.947050000000004},{"key":"8bf6e838a381bd54a71fab76ec32329ee9e85502264bce18bfd4dce5416f5ef3","facility":"Sunstone Medical, PC","city":"Rockville","region":"Maryland","country":"United States","lat":39.084000000000003,"lon":-77.152760000000001},{"key":"1a9055771782109a22253dda7644c3735bc7758f34ad52e7af1cb4208b995f4b","facility":"Interdisciplinary Substance Use and Brain Injury (ISUBI)","city":"Albuquerque","region":"New Mexico","country":"United States","lat":35.084490000000002,"lon":-106.65114},{"key":"53cb5faca3c60ecf068797736403edeb0302d95d0a85337b9536bbc345ef7916","facility":"Connecticut Mental Health Center - Yale School of Medicine","city":"New Haven","region":"Connecticut","country":"United States","lat":41.308149999999998,"lon":-72.928160000000005},{"key":"281c2eb56c8da95ba692a4789013f5bedb7069494aeb666eb410ca73d4c419da","facility":"Ohio State University Department of Psychiatry and Behavioral Health at the Davis Medical Research Center","city":"Columbus","region":"Ohio","country":"United States","lat":39.961179999999999,"lon":-82.99879},{"key":"e9371a41662463aee2a73b489b08fd54498561d5f98b540ab6947525b5b46514","facility":"Baylor College of Medicine","city":"Houston","region":"Texas","country":"United States","lat":29.763280000000002,"lon":-95.36327},{"key":"9b630a2a90cc4073ef88d0ddbb37bf0acd68f69db35ab18518826ea459738714","facility":"Combat Stress","city":"Leatherhead","region":"Surrey","country":"United Kingdom","lat":51.296520000000001,"lon":-0.33379999999999999}],"enrollment":{"sum":878,"known_trials":13},"registry_checked_at_utc":"2026-10-09 01:24:43"}